Aggarwal Himanshu, Saxena Anurag, Lubana Parvinder S, Mathur R K, Jain D K
Department of Surgery, M.G.M. Medical College and M.Y. Group of Hospitals, Indore, Madhya Pradesh, India.
J Cosmet Dermatol. 2008 Mar;7(1):43-9. doi: 10.1111/j.1473-2165.2008.00360.x.
Numerous treatments have been attempted with unsatisfactory results using either single or combination modalities for treatment of keloids and hypertrophic scars. The aim of our study was to determine the effectiveness and safety of bleomycin in the treatment of hypertrophic scars and keloids.
This study included 50 patients with keloids and hypertrophic scars. Bleomycin was administered through multiple superficial puncture technique. Three applications were given at intervals of 15 days each, followed by a fourth and final application 2 months after the last application. Final results were read 2 months after the last application. Results were evaluated according to change in size as follows: Group Response. a. Complete flattening (100% regression). b. Significant flattening (75-99% regression). c. Adequate flattening (50-74% regression). d. Inadequate flattening (less than 50%). Patients were assessed for any complication of bleomycin (systemic as well as local) and recurrence of keloids and hypertrophic scars. Regular follow-up for side-effects was done for 18 months.
Out of 50 patients, complete flattening was observed in 22 cases (44%); significant flattening in 11 cases (22%); and adequate flattening was observed in 7 cases (14%). Only 10 cases (20%) did not show any satisfactory flattening. Pruritus was relieved completely in 40 patients (88.88%). Recurrence was seen in seven patients.
Bleomycin is easy to administer, is cheap, shows high regression rate, and has minimum complication and recurrence. Thus, it can be used as the first-line treatment modality for management of keloids and hypertrophic scars.
对于瘢痕疙瘩和增生性瘢痕,无论是采用单一治疗方式还是联合治疗方式,都尝试过多种治疗方法,但效果均不理想。我们研究的目的是确定博来霉素治疗增生性瘢痕和瘢痕疙瘩的有效性和安全性。
本研究纳入了50例瘢痕疙瘩和增生性瘢痕患者。采用多点浅表穿刺技术给予博来霉素。每隔15天给药3次,最后一次给药2个月后进行第四次也是最后一次给药。在最后一次给药2个月后读取最终结果。根据大小变化评估结果如下:组反应。a. 完全扁平(100%消退)。b. 显著扁平(75 - 99%消退)。c. 充分扁平(50 - 74%消退)。d. 扁平不足(小于50%)。评估患者是否有博来霉素的任何并发症(全身和局部)以及瘢痕疙瘩和增生性瘢痕的复发情况。对副作用进行了18个月的定期随访。
50例患者中,22例(44%)观察到完全扁平;11例(22%)显著扁平;7例(14%)观察到充分扁平。只有10例(20%)未显示出任何令人满意的扁平效果。40例患者(88.88%)瘙痒完全缓解。7例患者出现复发。
博来霉素易于给药,价格便宜,消退率高,并发症和复发率最低。因此,它可作为瘢痕疙瘩和增生性瘢痕治疗的一线治疗方式。